Login to Your Account

Cempra moves toward goal line with solithromycin

By Marie Powers
Staff Writer

Tuesday, December 17, 2013

As expected, Cempra Inc. initiated Solitaire-IV, its global intravenous (I.V.)-to-oral Phase III trial of solithromycin (CEM-101) before year-end in patients with community-acquired bacterial pneumonia (CABP). The trial, which the company disclosed after Monday’s market close, joins Solitaire-Oral, the first global Phase III study of solithromycin in CABP patients, which initiated enrollment in December 2012.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription